Over the past 12 months, 5 insiders at Day One Biopharmaceuticals, Inc. filed 13 open-market SEC Form 4 transactions on DAWN: 0 purchases worth $0 and 13 sales worth $864K. Insiders have been net sellers over this period. The most recent filing was on Feb 17, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 17, 26 | Jeremy BenderCHIEF EXECUTIVE OFFICER | SELL | 15.5K | $11.60 | $179K |
| Feb 17, 26 | Adam DubowGen Counsel & Secretary | SELL | 6.4K | $11.60 | $74K |
| Feb 17, 26 | Lauren MerendinoChief Commercial Officer | SELL | 5.8K | $11.60 | $67K |
| Feb 17, 26 | Michael VasconcellesHead of Research and Dev. | SELL | 2.7K | $11.60 | $32K |
| Feb 17, 26 | Charles N York IICOO and CFO | SELL | 6.1K | $11.60 | $70K |
| Nov 17, 25 | Jeremy BenderCHIEF EXECUTIVE OFFICER | SELL | 15.9K | $8.91 | $142K |
| Nov 17, 25 | Adam DubowGen Counsel & Secretary | SELL | 4.3K | $8.91 | $38K |
| Nov 17, 25 | Lauren MerendinoChief Commercial Officer | SELL | 3.7K | $8.91 | $33K |
| Nov 17, 25 | Charles N York IICOO and CFO | SELL | 4.1K | $8.91 | $36K |
| Aug 18, 25 | Jeremy BenderCHIEF EXECUTIVE OFFICER | SELL | 16.1K | $6.77 | $109K |
| Aug 18, 25 | Adam DubowGen Counsel & Secretary | SELL | 4.4K | $6.77 | $30K |
| Aug 18, 25 | Lauren MerendinoChief Commercial Officer | SELL | 3.8K | $6.77 | $25K |
| Aug 18, 25 | Charles N York IICOO and CFO | SELL | 4.1K | $6.77 | $28K |
| May 16, 25 | Jeremy BenderCHIEF EXECUTIVE OFFICER | SELL | 14.0K | $6.26 | $87K |
| May 16, 25 | Adam DubowGENERAL COUNSEL | SELL | 4.6K | $6.26 | $28K |
| May 16, 25 | Lauren MerendinoChief Commercial Officer | SELL | 3.9K | $6.26 | $25K |
| May 16, 25 | Charles N York IICOO, CFO AND SECRETARY | SELL | 4.3K | $6.26 | $27K |
| Feb 18, 25 | Jeremy BenderCHIEF EXECUTIVE OFFICER | SELL | 12.0K | $11.96 | $144K |
| Feb 18, 25 | Adam DubowGENERAL COUNSEL | SELL | 4.6K | $11.96 | $56K |
| Feb 18, 25 | Charles N York IICOO, CFO AND SECRETARY | SELL | 4.4K | $11.96 | $52K |
| Dec 10, 24 | Samuel C. BlackmanHEAD OF R&D | SELL | 30.0K | $13.31 | $399K |
| Nov 18, 24 | Jeremy BenderCHIEF EXECUTIVE OFFICER | SELL | 10.6K | $13.21 | $139K |
| Nov 18, 24 | Samuel C. BlackmanHEAD OF R&D | SELL | 2.2K | $13.21 | $29K |
| Nov 18, 24 | Adam DubowGENERAL COUNSEL | SELL | 3.2K | $13.21 | $42K |
| Nov 18, 24 | Charles N York IICOO, CFO AND SECRETARY | SELL | 2.6K | $13.21 | $34K |
| Nov 11, 24 | Samuel C. BlackmanHEAD OF R&D | SELL | 10.0K | $16.10 | $161K |
| Nov 8, 24 | Samuel C. BlackmanHEAD OF R&D | SELL | 18.3K | $16.17 | $295K |
| Nov 7, 24 | Samuel C. BlackmanHEAD OF R&D | SELL | 11.2K | $16.03 | $180K |
| Oct 31, 24 | Samuel C. BlackmanHEAD OF R&D | SELL | 500 | $16.02 | $8K |
| Sep 10, 24 | Samuel C. BlackmanHEAD OF R&D | SELL | 30.0K | $14.22 | $427K |
| Aug 16, 24 | Jeremy BenderCHIEF EXECUTIVE OFFICER | SELL | 10.7K | $14.00 | $150K |
| Aug 16, 24 | Samuel C. BlackmanHEAD OF R&D | SELL | 2.2K | $14.00 | $31K |
| Aug 16, 24 | Adam DubowGENERAL COUNSEL | SELL | 3.2K | $14.00 | $45K |
| Aug 16, 24 | Charles N York IICOO, CFO AND SECRETARY | SELL | 2.6K | $14.00 | $37K |
| Jul 16, 24 | Samuel C. BlackmanHEAD OF R&D | SELL | 20.0K | $16.01 | $320K |
| Jun 21, 24 | Saira RamasastryDirector | SELL | 10.0K | $13.19 | $132K |
| Jun 10, 24 | Samuel C. BlackmanHEAD OF R&D | SELL | 30.0K | $12.62 | $379K |
| May 16, 24 | Jeremy BenderCHIEF EXECUTIVE OFFICER | SELL | 7.9K | $16.08 | $127K |
| May 16, 24 | Samuel C. BlackmanHEAD OF R&D | SELL | 2.3K | $16.08 | $36K |
| May 16, 24 | Adam DubowGENERAL COUNSEL | SELL | 3.3K | $16.08 | $52K |
| May 16, 24 | Charles N York IICOO, CFO AND SECRETARY | SELL | 2.7K | $16.08 | $43K |
| May 10, 24 | Samuel C. BlackmanHEAD OF R&D | SELL | 10.0K | $16.37 | $164K |
| May 3, 24 | Jeremy BenderCHIEF EXECUTIVE OFFICER | SELL | 9.2K | $17.85 | $163K |
| May 3, 24 | Charles N York IICOO, CFO AND SECRETARY | SELL | 8.1K | $17.85 | $144K |
| May 2, 24 | Jeremy BenderCHIEF EXECUTIVE OFFICER | SELL | 6 | $17.94 | $108 |
| May 2, 24 | Charles N York IICOO, CFO AND SECRETARY | SELL | 200 | $17.90 | $4K |
| May 1, 24 | Jeremy BenderCHIEF EXECUTIVE OFFICER | SELL | 70.1K | $17.88 | $1.3M |
| May 1, 24 | Charles N York IICOO, CFO AND SECRETARY | SELL | 52.2K | $17.89 | $934K |
| Apr 18, 24 | Samuel C. BlackmanHEAD OF R&D | SELL | 10.0K | $16.02 | $160K |
| Mar 25, 24 | Samuel C. BlackmanHEAD OF R&D | SELL | 10.0K | $16.01 | $160K |
Over the past 12 months, insiders at Day One Biopharmaceuticals, Inc. filed 0 open-market purchases worth $0 and 13 sales worth $864K on DAWN, which makes them net sellers over the period. The most recent Form 4 was filed on Feb 17, 26.
5 different insiders at Day One Biopharmaceuticals, Inc. filed open-market SEC Form 4 transactions on DAWN over the last 12 months.
InsiderTape plots every DAWN insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Day One Biopharmaceuticals, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →